Journal: Journal of Alzheimer's disease : JAD

Article Title: CCL23: A CHEMOKINE ASSOCIATED WITH PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE

doi: 10.3233/JAD-190753

Figure Lengend Snippet: Demographic characteristics of each study. Variables without a normal distribution (age and follow-up) are expressed as median (IQR), and categorical variables (sex) are expressed as the proportion of patients who presented the specified condition. Abbreviations: NINCDS-ADRDA: National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease and Related Disorders Association; NIA-AA: National Institute on Aging-Alzheimer’s Association.

Article Snippet: The details of each study are summarized in and are more extensively reported in the supplemental data . table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Study 1 (n=47) Study 2 (n=200) Study 3 (n=74) Study 4 (n=332) Center Hospital Universitari Vall d’Hebron, Barcelona, Spain Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Alzheimer Center, VU Medical Center, Amsterdam, Netherlands Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO Type of study Cross-sectional Cross-sectional Longitudinal case-control Longitudinal Follow-up (years) N/A N/A 2.6 (2–3.1) 5.4 (2.5–7.6) Subjects 36 AD patients 11 cognitive normal patients 50 AD patients 50 MCI patients 50 patients with other dementias 50 cognitive normal patients 74 MCI patients 332 community-dwelling patients (>60 years) Diagnostic criteria NINCDS-ADRDA NIA-AA NIA-AA NINCDS-ADRDA Age (years) 77 (72.5–83) 67 ± 0.64 68 (62–72) 72 (66.5–78) Sex (female) 66.7% 55.2% 32.1% 60.1% CCL23 measurement Human MPIF-1 ELISA Kit RayBio, RayBiotech Inc, Norcross, GA Human CCL23/MPIF-1 DuoSet ELISA Development System, R&D Systems Inc, Minneapolis, MN Human CCL23/MPIF-1 DuoSet ELISA Development System, R&D Systems Inc, Minneapolis, MN Discovery MAP ® v. 3.3, Myriad RBM, Austin, TX Biospecimen Serum Plasma Plasma Plasma and CSF Open in a separate window caption a8 Demographic characteristics of each study.

Techniques: Diagnostic Assay, Enzyme-linked Immunosorbent Assay

Journal: Journal of Alzheimer's disease : JAD

Article Title: CCL23: A CHEMOKINE ASSOCIATED WITH PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE

doi: 10.3233/JAD-190753

Figure Lengend Snippet: A. Correlation between plasma CCL23 levels and MMSE scores in study 2 (N=200) (R=−0.2, p=0.008). B. Correlation between plasma CCL23 levels and CSFCCL23 levels in patients in cohort 4 (N=332) (R=0.509, p<0.0001) C. Box plot comparing CSF CCL23 levels in patients with CDRs of 0, 0.5 and 1 at baseline. The thick line represents the p value of the Kruskal-Wallis test (p=0.005) and the thin line represents the p value of the post hoc comparison with Bonferroni’s correction (p=0.01). In the box plots, *p<0.05, **p<0.01, ***p<0.001, and the values are presented as the median and IQR.

Article Snippet: The details of each study are summarized in and are more extensively reported in the supplemental data . table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Study 1 (n=47) Study 2 (n=200) Study 3 (n=74) Study 4 (n=332) Center Hospital Universitari Vall d’Hebron, Barcelona, Spain Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Alzheimer Center, VU Medical Center, Amsterdam, Netherlands Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO Type of study Cross-sectional Cross-sectional Longitudinal case-control Longitudinal Follow-up (years) N/A N/A 2.6 (2–3.1) 5.4 (2.5–7.6) Subjects 36 AD patients 11 cognitive normal patients 50 AD patients 50 MCI patients 50 patients with other dementias 50 cognitive normal patients 74 MCI patients 332 community-dwelling patients (>60 years) Diagnostic criteria NINCDS-ADRDA NIA-AA NIA-AA NINCDS-ADRDA Age (years) 77 (72.5–83) 67 ± 0.64 68 (62–72) 72 (66.5–78) Sex (female) 66.7% 55.2% 32.1% 60.1% CCL23 measurement Human MPIF-1 ELISA Kit RayBio, RayBiotech Inc, Norcross, GA Human CCL23/MPIF-1 DuoSet ELISA Development System, R&D Systems Inc, Minneapolis, MN Human CCL23/MPIF-1 DuoSet ELISA Development System, R&D Systems Inc, Minneapolis, MN Discovery MAP ® v. 3.3, Myriad RBM, Austin, TX Biospecimen Serum Plasma Plasma Plasma and CSF Open in a separate window caption a8 Demographic characteristics of each study.

Techniques:

Journal: Journal of Alzheimer's disease : JAD

Article Title: CCL23: A CHEMOKINE ASSOCIATED WITH PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE

doi: 10.3233/JAD-190753

Figure Lengend Snippet: A. Bar plot representing the probabilities of MCI progression to AD. The light bars represent patients with CCL23 levels lower than 265 pg/mL, and the dark bars are those with levels higher than 265 pg/mL (p=0.03). B. Kaplan-Meier survival analysis of patients with CCL23 levels higher or lower than 265 pg/mL (p=0.02). C. Bar plot representing the probabilities of the progression of patients with a CDR of 0.5 to a CDR >0.5. The light bars represent patients with CSF CCL23 levels lower than 7080 pg/mL, and the dark bars represent those with levels higher than 7080 pg/mL (p=0.001). D. Kaplan-Meier survival analysis dividing patients into two groups depending on whether their CCL23 levels were higher or lower than 7080 pg/mL (p<0.0001).

Article Snippet: The details of each study are summarized in and are more extensively reported in the supplemental data . table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Study 1 (n=47) Study 2 (n=200) Study 3 (n=74) Study 4 (n=332) Center Hospital Universitari Vall d’Hebron, Barcelona, Spain Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Alzheimer Center, VU Medical Center, Amsterdam, Netherlands Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO Type of study Cross-sectional Cross-sectional Longitudinal case-control Longitudinal Follow-up (years) N/A N/A 2.6 (2–3.1) 5.4 (2.5–7.6) Subjects 36 AD patients 11 cognitive normal patients 50 AD patients 50 MCI patients 50 patients with other dementias 50 cognitive normal patients 74 MCI patients 332 community-dwelling patients (>60 years) Diagnostic criteria NINCDS-ADRDA NIA-AA NIA-AA NINCDS-ADRDA Age (years) 77 (72.5–83) 67 ± 0.64 68 (62–72) 72 (66.5–78) Sex (female) 66.7% 55.2% 32.1% 60.1% CCL23 measurement Human MPIF-1 ELISA Kit RayBio, RayBiotech Inc, Norcross, GA Human CCL23/MPIF-1 DuoSet ELISA Development System, R&D Systems Inc, Minneapolis, MN Human CCL23/MPIF-1 DuoSet ELISA Development System, R&D Systems Inc, Minneapolis, MN Discovery MAP ® v. 3.3, Myriad RBM, Austin, TX Biospecimen Serum Plasma Plasma Plasma and CSF Open in a separate window caption a8 Demographic characteristics of each study.

Techniques:

Journal: Journal of Alzheimer's disease : JAD

Article Title: CCL23: A CHEMOKINE ASSOCIATED WITH PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE

doi: 10.3233/JAD-190753

Figure Lengend Snippet: A. Bar plot representing the different clinical groups according to APOE genotype in study 2 (p=0.005). This is represented by the thick line on the graph. The AD patient group had more APOE ε4 carriers than the other dementias and control groups (p=0.02 in both cases) and is represented by the thin line. B. Box plot of plasma CCL23 levels in study 2 comparing APOE ε4 carriers and noncarriers (p=0.017). C. Correlation of tau and CCL23 levels in the CSF (R=0.172, p=0.002) in study 4. D. Correlation of P-tau and CCL23 levels in the CSF (R=0.17, p=0.002) in study 4. In the box plots, *p<0.05, **p<0.01, ***p<0.001, and the values are presented as the median and IQR.

Article Snippet: The details of each study are summarized in and are more extensively reported in the supplemental data . table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Study 1 (n=47) Study 2 (n=200) Study 3 (n=74) Study 4 (n=332) Center Hospital Universitari Vall d’Hebron, Barcelona, Spain Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Alzheimer Center, VU Medical Center, Amsterdam, Netherlands Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO Type of study Cross-sectional Cross-sectional Longitudinal case-control Longitudinal Follow-up (years) N/A N/A 2.6 (2–3.1) 5.4 (2.5–7.6) Subjects 36 AD patients 11 cognitive normal patients 50 AD patients 50 MCI patients 50 patients with other dementias 50 cognitive normal patients 74 MCI patients 332 community-dwelling patients (>60 years) Diagnostic criteria NINCDS-ADRDA NIA-AA NIA-AA NINCDS-ADRDA Age (years) 77 (72.5–83) 67 ± 0.64 68 (62–72) 72 (66.5–78) Sex (female) 66.7% 55.2% 32.1% 60.1% CCL23 measurement Human MPIF-1 ELISA Kit RayBio, RayBiotech Inc, Norcross, GA Human CCL23/MPIF-1 DuoSet ELISA Development System, R&D Systems Inc, Minneapolis, MN Human CCL23/MPIF-1 DuoSet ELISA Development System, R&D Systems Inc, Minneapolis, MN Discovery MAP ® v. 3.3, Myriad RBM, Austin, TX Biospecimen Serum Plasma Plasma Plasma and CSF Open in a separate window caption a8 Demographic characteristics of each study.

Techniques:

Journal: Frontiers in Immunology

Article Title: The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease

doi: 10.3389/fimmu.2026.1758367

Figure Lengend Snippet: Intergroup comparison of CCL23 protein expression among the Kawasaki disease (KD) group, fever control (FC) group, and healthy control (HC) group.

Article Snippet: Meanwhile, the quantitative detection of CCL23 protein was conducted using the Human CCL23 ELISA Kit (Boster Biological Technology, Product No.: EK1224) in strict accordance with the kit instructions.

Techniques: Comparison, Expressing, Control

Journal: Frontiers in Immunology

Article Title: The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease

doi: 10.3389/fimmu.2026.1758367

Figure Lengend Snippet: Diagnostic accuracy analysis of CC Chemokine Ligand 23 (CCL23) for Kawasaki disease (KD). (A) Comparison between the KD group and the fever control (FC) group; (B) Comparison between the KD group and the healthy control (HC) group; (C) Comparison between the KD group and the combined FC and HC groups.

Article Snippet: Meanwhile, the quantitative detection of CCL23 protein was conducted using the Human CCL23 ELISA Kit (Boster Biological Technology, Product No.: EK1224) in strict accordance with the kit instructions.

Techniques: Diagnostic Assay, Comparison, Control